Navigation Links
Endologix Reports 30% Third Quarter 2010 Revenue Growth
Date:10/27/2010

f reps at quarter end to 61, and we continue to expect to meet our targeted 30% increase in the sales force during 2010."

Mr. Krist added, "Accounts receivable days outstanding were 59 days at the end of the third quarter, down from 61 days at the end of the second quarter.  The DSO improvement from the second quarter contributed to the generation of $444,000 in free cash flow during the third quarter, positioning the Company to achieve our goal of fully funding our 2010 planned investments in the sales force expansion and new product pipeline with internally generated cash flow."

Based on the results for the first nine months of 2010, the Company is increasing its full year 2010 revenue guidance and reiterating its full year 2010 earnings per share guidance.  The Company now anticipates 2010 revenue to be in the range of $66 million to $67 million, up from the previous guidance range of $62 million to $66 million, representing annual growth of 26% to 28%.  For the full year 2010, the Company expects to generate positive earnings per share excluding the impact of litigation, acquisitions or other business development transactions.

For the full year 2011, the Company anticipates total revenue to be in the range of $78 million to $82 million, representing growth of 16 % to 24%.  In 2011, the Company expects to generate a net loss of $0.25 to $0.30 per share due to planned investments in building a direct sales force in Europe and developing the acquired Nellix technology in anticipation of a commercial launch in Europe and the initiation of a U.S. IDE clinical trial in 2012.  The Company's 2011 loss per share guidance also includes ongoing investments in the U.S. sales force, research and development and clinical initiatives, and excludes the potential impact of adverse litigation outcomes, acquisitions or other business development transactions.

Conference Call InformationEndologix management will host a confere
'/>"/>

SOURCE Endologix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Endologix Comments on Alleged Patent Infringement
2. Endologix Responds to Alleged Patent Infringement
3. Endologix to Report Third Quarter 2009 Financial Results on October 27, 2009
4. Endologix Reports 47% Third Quarter 2009 Revenue Growth
5. Endologix Files Motion to Discontinue Court Proceedings Related to Alleged Patent Infringement
6. Endologix Enters Development Agreement and Exclusive License for Balloon Expandable Stent Technology
7. Endologix Receives CE Mark Approval for Expanded Line of Powerlink Products and PowerFit Aortic Extensions
8. Endologix to Report Third Quarter 2010 Financial Results on October 27, 2010
9. Endologix Announces Publication of Clinical Trial Results Supporting Anatomical Fixation with a Suprarenal Aortic Extension
10. Endologix to Present at Oppenheimer 21st Annual Healthcare Conference
11. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... , Sept. 23, 2014  Medela announced today ... Biomedical Company (ABC), assigning Medela as the exclusive distributor ... known as the Medela Enteral Feeding Pump. Through this ... help NICU parents and healthcare professionals by offering a ... Medela Enteral Feeding Pump is integral to the delivery ...
(Date:9/23/2014)... Sept. 23, 2014 A case report and ... SynCardia temporary Total Artificial Heart into a patient with ... were reversed, along with other abnormalities. ... the SynCardia Total Artificial Heart to treat a patient ... and video in the Journal of Visualized Experiments show ...
(Date:9/23/2014)... September 23, 2014 BerGenBio ... company, today announces it has been granted a ... Award from the UK,s Wellcome Trust to develop ... novel cancer target. The Wellcome Trust ... fund especially promising, innovative new therapeutic concepts through ...
Breaking Medicine Technology:Medela Enters Exclusive Enteral Feeding Pump Agreement with Atlanta Biomedical Company 21st Use of the SynCardia Total Artificial Heart in a 17-Year-Old Congenital Heart Disease Patient at Pediatric Hospital 21st Use of the SynCardia Total Artificial Heart in a 17-Year-Old Congenital Heart Disease Patient at Pediatric Hospital 31st Use of the SynCardia Total Artificial Heart in a 17-Year-Old Congenital Heart Disease Patient at Pediatric Hospital 4BerGenBio Granted a Prestigious Wellcome Trust Seeding Drug Discovery Award 2BerGenBio Granted a Prestigious Wellcome Trust Seeding Drug Discovery Award 3
(Date:9/23/2014)... York, NY (PRWEB) September 23, 2014 ... products, revenue for the Fruit and Vegetable ... produce consumption and fruit prices benefited operators over ... the industry follow unique preference and demographic trends, ... aging US population. While per capita fruit and ...
(Date:9/23/2014)... the results of their cancer research at ESMO ... Joint Symposium: ESMO-ASCO: The Evolution of the ... AM - 12:30 PM, Room: Granada, Abstract 121IN: ... new forms of cancer clinical research? The example ... Paper session: Melanoma and other skin tumors , ...
(Date:9/23/2014)... The "area under the curve of oxygen desaturation" ... to monitoring blood oxygen levels during procedures using sedation, ... Analgesia . , The AUC Desat provides information ... also on the depth, duration, and rate of episodes ... Niklewski, PhD, of University of Cincinnati and colleagues reports ...
(Date:9/23/2014)... has awarded $10.1 million in supplemental funding to bolster ... of sex in preclinical and clinical studies. , This ... is a catalyst for considering sex as a fundamental ... in preclinical research can obscure key findings related to ... approach will result in greater awareness of the need ...
(Date:9/23/2014)... of four dogs will develop cancer in their lifetime ... cases. , A team of researchers from the University ... develop a new user-friendly electronic system for diagnosing lymphoma ... monitoring. , Marketed as cLBT (canine lymphoma blood ... to track the remission monitoring status of a dog ...
Breaking Medicine News(10 mins):Health News:Fruit & Vegetable Markets in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Fruit & Vegetable Markets in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:EORTC presentations at ESMO 2014 Congress 2Health News:EORTC presentations at ESMO 2014 Congress 3Health News:New measure provides more data on oxygen levels during sedation 2Health News:New supplemental awards apply sex and gender lens to NIH-funded research 2Health News:New supplemental awards apply sex and gender lens to NIH-funded research 3Health News:New hope for beloved family pets 2
... Corporation,(CRM:TSX-V) announced today that it has opened a Center ... the Company,s second in the,Miami area, one of many ... of the Pembroke Pines Center brings the Company,s total ... Institute of Health, the prevalence rate of,hemorrhoids in the ...
... C-Span did to open,the door on Congressional proceedings ... is doing for medical professionals via its live,coverage ... Today is the innovative source of medical news ... credit to,physicians and other clinicians., From March ...
... The Bill & Melinda Gates Foundation,announced today that ... first,round of Grand Challenges Explorations, a US$100 million ... Proposals will,be accepted online at http://www.gcgh.org/explorations ... to submit a proposal by May 15,2008., ...
... Softgel Supplements Formulated for Easy Swallowing and ... ... Many things in life are,hard to swallow, but your vitamins shouldn,t ... a new,way to fuel the body with a complete product line ...
... to reach out to,wounded soldiers, Retired Army Reserve Lieutenant ... uplifting and rejuvenating weekend,retreats -- offered at no cost ... and relaxation for soldiers hurt in Iraq and Afghanistan., ... Terrorists,these brave men and women are now embarking on ...
... 2008) Real-world use of a novel drug-eluting stent ... clinical outcomes, according to one-year data from a large ... on the sirolimus-eluting Excel stent, are being reported today ... Annual Scientific Sessions in Partnership with ACC i2 Summit ...
Cached Medicine News:Health News:CRH Medical Corporation opens new center in Pembroke Pines Florida 2Health News:MedPage Today(R) Provides First-Time Live Video Coverage of Medical Meeting Press Conferences 2Health News:Gates Foundation Now Accepting Proposals for Grand Challenges Explorations 2Health News:Nature Made(R) Changes the Way America Takes Vitamins 2Health News:Nature Made(R) Changes the Way America Takes Vitamins 3Health News:Healing Wounds and Hearts: Warrior Weekend Helps Soldiers Relax and Recover 2Health News:Registry unveils 'real-world' data on novel excel stent 2
... for the Humphrey Field Analyzer, SITA ... shows less inter-test variability than Full ... of reproducibility as Full Threshold SWAP. ... with the earlier glaucoma damage detected ...
... you can trust its capabilities will ... cataract, and glaucoma therapy in one ... is the optimal system for photocoagulation, ... iridotomy. The push of a button ...
... The VISUCAM non-mydriatic ... quality and simplicity of ... big enough to set ... photography, it features a ...
... YAG III is the new disruption ... in particular for applications in posterior ... the YAG laser is also used ... IOL polishing. It's another milestone in ...
Medicine Products: